Table 2 Baseline demographics
Total group (n = 1555) | Amyloid negative (n = 573) | Amyloid positive (n = 982) | Stage 1 (n = 120) | Stage 2 (n = 160) | Stage 3 (n = 464) | Stage 4+ (n = 238) | Post hoc group differences | |
|---|---|---|---|---|---|---|---|---|
Years of follow-up, mean (range) | 2.79 (0.25–7.09) | 3.31 (0.46–7.07) | 2.49 (0.25–7.09) | 2.94 (0.56–6.38) | 2.96 (0.46–7.06) | 2.69 (0.25–7.09) | 1.36 (0.26–4.45) | Amyloid negative, stages 1, 2 > 3 > 4 |
Age | 72.45 ± 7.8 | 72.82 ± 7.1 | 72.24 ± 8.2 | 74.72 ± 6.5 | 74.19 ± 7.7 | 71.79 ± 8.0 | 70.55 ± 9.1 | Stage 1, 2 > amyloid negative > stages 3, 4 |
Female, n (%) | 763 (50) | 311 (55) | 452 (47) | 66 (56) | 84 (54) | 196 (43) | 106 (45) | Amyloid negative, stages 4, 2, 1 > 3 |
Education years | 15.37 ± 3.3 | 15.94 ± 3.1 | 15.05 ± 3.4 | 15.94 ± 3.2 | 15.68 ± 3.2 | 15.13 ± 3.3 | 14.01 ± 3.7 | Amyloid negative, stage 1, 2 > 3 > 4 |
MMSE | 27.08 ± 3.8 | 29.11 ± 1.1 | 25.62 ± 4.3 | 29.06 ± 1.0 | 28.45 ± 1.7 | 26.43 ± 2.7 | 20.08 ± 4.2 | Amyloid negative, stage 1 > 2 > 3 > 4 |
Cohorts, n (%) | ||||||||
HABS | 259 (17) | 194 (34) | 65 (6) | 38 (31) | 27 (17) | – | – | |
ADNI | 829 (53) | 323 (55) | 506 (52) | 49 (42) | 72 (45) | 288 (62) | 98 (41) | |
NACC | 201 (13) | – | 201 (21) | 29 (25) | 23 (14) | 84 (18) | 65 (27) | |
ADC | 178 (11) | – | 178 (18) | – | 15 (9) | 87 (19) | 76 (32) | |
EMIF-AD | 73 (5) | 53 (9) | 20 (2) | 2 (2) | 18 (11) | – | – | |
EMIF-90+ | 15 (1) | 3 (1) | 12 (1) | 2 (2) | 5 (3) | 5 (1) | – | |